Sarcoma News and Research

RSS

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

The key to immune-based cancer therapies lies in the ability to exploit some weakness within the tumor and its environment or to elude cancer's offenses. Writing in the journal Scientific Reports, researchers led by a group from the Roswell Park Cancer Institute Center for Immunotherapy have shared new insights about a subset of T cells that appear to do both those things, inhibiting cancer growth at the same time that they enhance the tumor-killing powers of other immune cells.

19 Oct 2015

Research: Epigenetic factor reduces sensitivity of breast cancer cells to common cancer drug

A surprising, paradoxical relationship between a tumor suppressor molecule and an oncogene may be the key to explaining and working around how breast cancer tumor cells become desensitized to a common cancer drug, found researchers at the Perelman School of Medicine at the University of Pennsylvania.

13 Oct 2015

YK-4-279 compound works against some forms of leukemia: Study

A compound discovered and developed by a team of Georgetown Lombardi Comprehensive Cancer Center researchers that halts cancer in animals with Ewing sarcoma and prostate cancer appears to work against some forms of leukemia, too.

12 Oct 2015

UT Southwestern investigators develop new strategy to classify cancers caused by KRAS mutations

UT Southwestern Medical Center researchers have developed a classification for cancers caused by KRAS, the most frequently mutated gene in cancer, that could eventually help oncologists choose more effective, customized cancer therapies.

8 Oct 2015

UT Southwestern surgeons help pioneer minimally invasive ear surgery

UT Southwestern Medical Center surgeons are helping to pioneer a trend that extends the advantages and benefits of minimally invasive surgery to patients who need middle ear surgery.

23 Sep 2015

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

21 Sep 2015

Surgeons use 3D printed implant in patient diagnosed with chest wall sarcoma

After being diagnosed with a chest wall sarcoma, a 54-year-old Spanish man's surgical team made the decision to remove his sternum and a portion of his rib cage and replace it with an implant.

14 Sep 2015

American Income Life donates $10,000 to Sarcoma Foundation of America

American Income Life Insurance Company, headquartered in Waco, TX, in partnership with State General Agents Tom Williams and David Zophin, donated $10,000 to the Sarcoma Foundation of America (South Florida Chapter) as part of the Company's Closer to the Heart program of charitable giving.

14 Sep 2015

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

The Children's Hospital at Montefiore and the NCI-designated Albert Einstein Cancer Center today announced receipt of $1.3 million grant from the National Cancer Institute, part of the National Institutes of Health.

9 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

Discovery could open up door for cancer research and treatment

Florida State University researchers have taken a big step forward in the fight against cancer with a discovery that could open up the door for new research and treatment options.

28 Aug 2015

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Kidney Cancer is among the 10 most diagnosed cancers in both men and women in the United States, and it is estimated that more than 60,000 new cases of kidney cancer will be diagnosed in 2015.

27 Aug 2015

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Researchers from Memorial Sloan Kettering Cancer Center have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients' tumors rather than where their cancer originated.

20 Aug 2015

Organ transplant recipients more likely to develop melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and three times more likely to die of the dangerous skin cancer, suggests new research led by a Johns Hopkins Bloomberg School of Public Health student.

14 Aug 2015

Researchers show how realistic environments affect growth of cancer tumors in bones

Researchers at Rice University and University of Texas MD Anderson Cancer Center have developed a way to mimic the conditions under which cancer tumors grow in bones.

6 Aug 2015

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, announced that it has committed more than $29.3 million in new funds to accelerate cancer immunology research and cancer immunotherapy clinical development in the United States, Australia, Canada, France, Sweden, Switzerland, and The Netherlands.

5 Aug 2015

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Daiichi Sankyo Europe and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine published clinical trial results demonstrating that the investigational drug, PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor regressions in most patients with tenosynovial giant cell tumor, a rare, locally aggressive neoplasm of the joint or tendon sheath.

31 Jul 2015

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Researchers from Ludwig-Maximilians-Universitaet in Munich have elucidated at the molecular level how an otherwise innocuous inherited mutation that is quite common in European populations interacts with a spontaneous somatic mutation to promote the development of Ewing's sarcoma.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Sarcoma News and Research

Special CD4+ T cells appear to inhibit cancer growth, enhance tumor-killing powers of other immune cells

Research: Epigenetic factor reduces sensitivity of breast cancer cells to common cancer drug

YK-4-279 compound works against some forms of leukemia: Study

UT Southwestern investigators develop new strategy to classify cancers caused by KRAS mutations

UT Southwestern surgeons help pioneer minimally invasive ear surgery

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Surgeons use 3D printed implant in patient diagnosed with chest wall sarcoma

American Income Life donates $10,000 to Sarcoma Foundation of America

CHAM, AECC receive $1.3 million NCI grant to advance more effective bone cancer treatments for children

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Discovery could open up door for cancer research and treatment

New NCCN Guidelines for Patients and NCCN Quick Guide for Kidney Cancer published

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Organ transplant recipients more likely to develop melanoma

Researchers show how realistic environments affect growth of cancer tumors in bones

CRI commits $29.3 million in new funds to accelerate development of cancer immunotherapies

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

LMU researchers reveal role of mutations in development of Ewing's sarcoma

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News